Nacer Azli, MD

Articles

A Phase II Randomized Study of Doxorubicin Alternated With Docetaxel vs Sequential Administration of Four Cycles of Docetaxel Followed by Four Cycles of Doxorubicin as First-Line Chemotherapy in Metastatic Breast Cancer Patients

R. Paridaens;G. Georgoulias;H. Samonnig;S. Van Belle;Christoph C. Zielinski, MD;H. Hausmaninger;P. Willemse;Y. Boudraa;Nacer Azli, MD

August 2nd 2000

From March 1996 to March 1998, 106 patients with untreated metastatic breast cancer (MBC) were treated with docetaxel (Taxotere) (100 mg/m²) and doxorubicin (75 mg/m²) on an alternating cycle-by-cycle (doxorubicin, docetaxel, doxorubicin, etc) or sequential (four cycles of docetaxel, then four cycles of doxorubicin) basis, every 3 weeks, for a maximum of eight cycles.

Docetaxel Combined With Vinorelbine: Phase I Results and New Study Designs

Pierre Fumoleau, MD;Valerie Delecroix, MD;Regine Féty, PhD;Nacer Azli, MD

June 1st 1997

This was a phase I dose-finding and pharmacokinetic study of vinorelbine (Navelbine) and docetaxel (Taxotere) as first-line chemotherapy for metastatic breast cancer. Vinorelbine dose, 20 or 22.5 mg/m², on days 1 and 5, was followed on day 1 by docetaxel every 21 days, in doses increasing from 60 to 100 mg/m².